Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Carisma Therapeutics ( (CARM) ) has shared an announcement.
Carisma Therapeutics Inc. announced a revised operating plan, including a significant workforce reduction of 34%, affecting areas like R&D and finance, and the termination of CFO Richard Morris. The company is halting development of its HER2-targeting CT-0525 due to competitive pressures, pivoting towards mRNA/lipid nanoparticle CAR-M programs with ModernaTX Inc., and exploring treatments for fibrosis and neurodegeneration. These changes aim to streamline operations and focus on promising therapeutic areas.
Find detailed analytics on CARM stock on TipRanks’ Stock Analysis page.